Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Heart Diseases 1Colorectal Neoplasms 1Cardiotoxicity 1

Interventions

Cytarabine 58Etoposide 24Daunorubicin 22Filgrastim 18Idarubicin 16Mitoxantrone 13Busulfan 13tipifarnib 11fludarabine phosphate 10Gemtuzumab 10Cyclophosphamide 10Peripheral Blood Stem Cell Transplantation 9Flow Cytometry 9sargramostim 8Clofarabine 8Methotrexate 7Gene Expression Profiling 7Cyclosporine 7Topotecan 6Azacitidine 6valspodar 5alvocidib 5Granulocyte Colony-Stimulating Factor 5Antilymphocyte Serum 5aldesleukin 4Radiotherapy 4Observation 4Bortezomib 4Arsenic Trioxide 4Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Monocytic, Acute × Antineoplastic Agents × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡